219 / 1835
Patients (n = 23)
Percent Change in Tumor Burden
CR (22%)
PR 65%
SD(13%)
25
0
–25
–50
–75
–100
On treatment, ongoing response
Off treatment without disease progression
a
Progressive disease, following
response or stable disease
Nivolumab in r&r HL
Best response
Ansell et al; ASH 2015